CYTK Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.…
Industry Peers
BiotechnologyKey Statistics
About Cytokinetics (NASDAQ: CYTK)
›
Cytokinetics (NASDAQ: CYTK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 673 employees.
The shares were at 50.78 USD on 20 November 2026, down 15.6% over 52 weeks. Its 52-week range is 50.32 USD to 88.31 USD, and it trades at the bottom of that range.
Its market capitalisation is 7.07B USD.
Cytokinetics reports return on equity of 119.0%.
Its debt exceeds its cash by 296.84M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 109.42 USD is 115.5% above the current price. The next earnings report is expected on 24 February 2027.